Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib (Q24594790)

13 November 2016

title

Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib (English)

1 reference

13 November 2016

0 references

0 references

Bartosz Chmielowski

Bartosz

Chmielowski

1 reference

20 October 2023

Antoni Ribas

Antoni

Ribas

1 reference

20 October 2023

Igor Puzanov

Igor

Puzanov

1 reference

20 October 2023

Grant A McArthur

Grant A

McArthur

1 reference

20 October 2023

Richard Kefford

Richard

Kefford

1 reference

20 October 2023

Keith T Flaherty

Keith T

Flaherty

1 reference

20 October 2023

Jeffrey A Sosman

Jeffrey A

Sosman

1 reference

20 October 2023

Stergios J Moschos

Stergios J

Moschos

1 reference

20 October 2023

Lynn Schuchter

Lynn

Schuchter

1 reference

20 October 2023

Anna C Pavlick

Anna C

Pavlick

1 reference

20 October 2023

Kevin B Kim

Kevin B

Kim

1 reference

20 October 2023

Rene Gonzalez

Rene

Gonzalez

1 reference

20 October 2023

Jeffrey S Weber

Jeffrey S

Weber

1 reference

20 October 2023

Thomas E Hutson

Thomas E

Hutson

1 reference

20 October 2023

Peter Hersey

Peter

Hersey

1 reference

20 October 2023

Donald Lawrence

Donald

Lawrence

1 reference

20 October 2023

Karl D Lewis

Karl D

Lewis

1 reference

20 October 2023

Ravi K Amaravadi

Ravi K

Amaravadi

1 reference

20 October 2023

H Jeffrey Lawrence

H Jeffrey

Lawrence

1 reference

20 October 2023

Yu Shyr

Shyr

1 reference

20 October 2023

Fei Ye

Fei

1 reference

20 October 2023

Jiang Li

Jiang

1 reference

20 October 2023

Keith B Nolop

Keith B

Nolop

1 reference

20 October 2023

Richard J Lee

Richard J

Lee

1 reference

20 October 2023

Andrew K Joe

Andrew K

Joe

1 reference

The New England Journal of Medicine

20 October 2023

language of work or name

English

0 references

publication date

23 February 2012

0 references

published in

0 references

volume

366

0 references

issue

0 references

page(s)

707-14

0 references

on focus list of Wikimedia project

ScienceSource

0 references

cites work

Improved survival with vemurafenib in melanoma with BRAF V600E mutation

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3724515

Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation

24 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3724515

Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma

24 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3724515

The RAF inhibitor PLX4032 inhibits ERK signaling and tumor cell proliferation in a V600E BRAF-selective manner

24 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3724515

Kinase-dead BRAF and oncogenic RAS cooperate to drive tumor progression through CRAF

24 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3724515

Discovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activity

24 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3724515

RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth

24 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3724515

Dissecting therapeutic resistance to RAF inhibition in melanoma by tumor genomic profiling

24 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3724515

Inhibition of Mutated, Activated BRAF in Metastatic Melanoma

24 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3724515

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

24 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3724515

Mutations of the BRAF gene in human cancer

24 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3724515

Ipilimumab plus dacarbazine for previously untreated metastatic melanoma

24 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3724515

New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)

24 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3724515

Randomized phase III study of temozolomide versus dacarbazine in the treatment of patients with advanced metastatic malignant melanoma

24 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3724515

RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E)

24 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3724515

Acquired resistance to BRAF inhibitors mediated by a RAF kinase switch in melanoma can be overcome by cotargeting MEK and IGF-1R/PI3K

7 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3724515

COT drives resistance to RAF inhibition through MAP kinase pathway reactivation

7 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3724515

RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF

7 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3724515

High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993

7 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3724515

Toxicity and response criteria of the Eastern Cooperative Oncology Group

7 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3724515

RAS mutations in cutaneous squamous-cell carcinomas in patients treated with BRAF inhibitors

7 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3724515

RG7204 (PLX4032), a selective BRAFV600E inhibitor, displays potent antitumor activity in preclinical melanoma models

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3724515

Differential sensitivity of melanoma cell lines with BRAFV600E mutation to the specific Raf inhibitor PLX4032.

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3724515

Phase III trial comparing concurrent biochemotherapy with cisplatin, vinblastine, dacarbazine, interleukin-2, and interferon alfa-2b with cisplatin, vinblastine, and dacarbazine alone in patients with metastatic malignant melanoma (E3695): a trial c

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3724515

Meta-analysis of phase II cooperative group trials in metastatic stage IV melanoma to determine progression-free and overall survival benchmarks for future phase II trials

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3724515

Melanoma biology and new targeted therapy

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3724515

Management of cutaneous melanoma

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3724515

Phase III trial of dacarbazine versus dacarbazine with interferon alpha-2b versus dacarbazine with tamoxifen versus dacarbazine with interferon alpha-2b and tamoxifen in patients with metastatic malignant melanoma: an Eastern Cooperative Oncology Gr

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3724515

Prognostic and clinicopathologic associations of oncogenic BRAF in metastatic melanoma.

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3724515

RAF inhibition and induction of cutaneous squamous cell carcinoma.

28 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3724515

Phase III multicenter randomized trial of the Dartmouth regimen versus dacarbazine in patients with metastatic melanoma

28 November 2018

1 reference

https://pubmed.ncbi.nlm.nih.gov/22356324

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Sensitive mutation detection in heterogeneous cancer specimens by massively parallel picoliter reactor sequencing

1 reference

https://pubmed.ncbi.nlm.nih.gov/22356324

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1056/NEJMOA1112302

1 reference

release_potun7fscfclhhx7iclag7wvkm

Fatcat ID

0 references

1 reference

1 reference

1 reference